Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03815175 · ClinicalTrials.gov registry record · NA
XIENCE 28 USA Study
A NA study, sponsored by Abbott Medical Devices.
- Completed
- Registry status
- NA
- Development phase
- 1,605
- Enrollment target
NCT03815175: Completed NA study, sponsored by Abbott Medical Devices.
NCT03815175 is a NA study that has completed, run by Abbott Medical Devices. The registered enrollment target is 1,605 participants, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (14% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03815175, a NA study, has completed, sponsored by Abbott Medical Devices.
- COMPLETED
- Registry status
- NA
- Development phase
- 1,605 participants
- Enrollment target
Study Summary
The XIENCE 28 USA Study is prospective, single arm, multi-center, open label, non-randomized trial to evaluate safety of 1-month (as short as 28 days) dual antiplatelet therapy (DAPT) in subjects at high risk of bleeding (HBR) undergoing percutaneous coronary intervention (PCI) with the approved XIENCE family (XIENCE Xpedition Everolimus Eluting Coronary Stent System \[EECSS\], XIENCE Alpine EECSS and XIENCE Sierra EECSS) of coronary drug-eluting stents.
Primary Outcome
All death: All deaths are considered cardiac unless an unequivocal non-cardiac cause can be established. Specifically, any unexpected death even in patients with coexisting potentially fatal non-cardiac disease (e.g.cancer, infection) should be classified as cardiac. MI Definition (Modified ARC): Patients present any of the following clinical or imaging evidence of ischemia: * Clinical symptoms of ischemia; * ECG changes indicative of new ischemia - new ST-T changes or new left bundle branch
Interventions
- DEVICE XIENCE
- DRUG DAPT (aspirin and/or P2Y12 receptor inhibitor)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,605 participants |
| Start Date | 2019-02-25 |
| Est. Completion | 2021-02-04 |
| Phase | NA |
What the finished NCT03815175 record still lists
NCT03815175 is an interventional study that assigns participants to a tested intervention. Its 1,605 participants enrollment target places it among the larger protocols in the corpus, above the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (14% higher).
The record links to 0 conditions, and to 2 interventions - of which XIENCE is the first listed.
NCT03815175 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03815175 about?
NCT03815175 is a clinical study titled "XIENCE 28 USA Study". The XIENCE 28 USA Study is prospective, single arm, multi-center, open label, non-randomized trial to evaluate safety of 1-month (as short as 28 days) dual antiplatelet therapy (DAPT) in subjects at high risk of bleeding (HBR) undergoing percutaneous coronary intervention (PCI) with the approved XIE...
What is the current status of trial NCT03815175?
This trial is currently completed. It is a NA study. The enrollment target is 1,605 participants. The study started on 2019-02-25. Estimated completion is 2021-02-04.
What interventions are being tested in trial NCT03815175?
The interventions under investigation include: XIENCE (DEVICE), DAPT (aspirin and/or P2Y12 receptor inhibitor) (DRUG).
Who is sponsoring clinical trial NCT03815175?
This trial is sponsored by Abbott Medical Devices, which has 261 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03815175's enrollment target sits among peer trials
1,605 63rd of 2000 higher than 1,938 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06271590 · 1,605 participants · NA
MagicTouch™Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small Vessels
- NCT00646022 · 1,600 participants
Natural History of Familial Carcinoid Tumor
- NCT03109197 · 1,600 participants
Sudden Unexplained Death in Childhood (SUDC) Registry
- NCT03511118 · 1,600 participants
Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI